A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia

A phase 3, randomized, open-label study evaluating the safety and efficacy of magrolimab in combination with azacitidine in previously untreated patients with TP53-mutant acute myeloid leukemia

Show other versions (1)
Bibliographic Details
Main Authors: Daver, N, Vyas, P, Chao, MP, Xing, G, Renard, C, Ramsingh, G, Sallman, DA, Wei, AH
Format: Conference item
Language:English
Published: Wiley 2022

Similar Items